Female Genital Schistosomiasis | NEJM
Perspective from The New England Journal of Medicine — Female Genital Schistosomiasis
Related Articles
A Randomized Trial of Intravenous Amino Acids for Kidney Protection | NEJM
Acute kidney injury (AKI) is a serious and common complication of cardiac surgery, for which reduced kidney perfusion is a key contributing factor. Intravenous amino…
TikTok · NEJM
125 likes, 3 comments. “In the latest video in our partnership with @drglaucomflecken, Cardiac Surgery is forced to consider the kidney. Watch as Dr. G…
Interview with Jonathan Oberlander on the implications of the 2024 U.S. elections for health care reform. | NEJM
Audio Interview from the New England Journal of Medicine — Interview with Jonathan Oberlander on the implications of the 2024 U.S. elections for health care…
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity | NEJM
Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide…
Aggressive Lymphoma after CD19 CAR T-Cell Therapy | NEJM
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…
Aggressive Lymphoma after CD19 CAR T-Cell Therapy | NEJM
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…
Avoiding Financial Toxicity for Patients from Clinicians’ Use of AI | NEJM
When AI tools recommend confirmatory diagnostic testing, patients may face new financial burdens if these recommendations are followed by their clinicians but not yet reflected…
Aggressive Lymphoma after CD19 CAR T-Cell Therapy | NEJM
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype | NEJM
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo-cont…
Aggressive Lymphoma after CD19 CAR T-Cell Therapy | NEJM
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…